脂质运载蛋白2在肝脏疾病发生发展中的作用

廖争光; 卫诗蕙; 杜丹玉; 孙立; 袁胜涛

doi:10.3969/j.issn.1001-5256.2022.09.044

脂质运载蛋白2在肝脏疾病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2022.09.044

中国药科大学药物科学研究院，江苏省新药筛选重点实验室，南京 210009

基金项目:

国家自然科学基金 (81773766)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：袁胜涛、廖争光负责研究选题；廖争光、卫诗蕙负责设计论文框架，起草论文；杜丹玉负责修订论文；孙立负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
袁胜涛，yuanst1967@163.com

计量
- 文章访问数: 376
- HTML全文浏览量: 269
- PDF下载量: 62
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-18
- 录用日期: 2022-03-20
- 出版日期: 2022-09-20

Role of lipocalin-2 in the development and progression of liver diseases

Jiangsu Key Laboratory for New Drug Screening, Institute of Pharmaceutical Research, China Pharmaceutical University, Nanjing 210009, China

Research funding:

National Natural Science Foundation of China (81773766)

More Information

Corresponding author: YUAN Shengtao, yuanst1967@163.com (ORCID: 0000-0002-5626-6532)

摘要

摘要: 脂质运载蛋白2(LCN2)最初是从感染猴空泡病毒40的小鼠肾细胞培养物中纯化得到的一种分泌糖蛋白，在炎症期间对细胞稳态控制以及应对细胞应激或损伤的反应中发挥着关键作用，被认为是风湿病、癌症、肝脏疾病和炎症性疾病的一种潜在的生物标志物。已有研究表明，LCN2在肝实质细胞和非实质细胞中表达并分泌入血，与急性肝损伤、肝硬化、病毒性肝炎、酒精性肝病、非酒精性脂肪性肝病以及肝细胞癌等的发生发展密切相关。本文总结了LCN2与肝脏疾病发病机制相关的动物实验和临床研究，以期为肝脏疾病的防治提供新思路和治疗靶点。
- 肝疾病 /
- 脂质运载蛋白2 /
- 病理过程
Abstract: Lipocalin-2 (LCN2) is a secreted glycoprotein originally purified from mouse kidney cells infected with simian virus 40 and plays a key role in the control of cellular homeostasis during inflammation and the response to cellular stress or injury, and it is considered a potential biomarker for rheumatic diseases, cancer, liver diseases, and inflammatory diseases. Studies have shown that LCN2 is expressed in hepatic parenchymal and nonparenchymal cells and is secreted into the bloodstream, and it is closely associated with the development and progression of acute liver injury, liver cirrhosis, viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, and hepatocellular carcinoma. This article summarizes the animal experiments and clinical studies on the association of LCN2 with the pathogenesis of liver diseases, in order to provide new ideas and therapeutic targets for the prevention and treatment of liver diseases.
- Liver Diseases /
- Lipocalin-2 /
- Pathologic Processes

HTML全文

参考文献(44)

[1]	MUSSAP M, DEGRANDI R, FRAVEGA M, et al. Acute kidney injury in critically ill infants: the role of urine Neutrophil Gelatinase-Associated Lipocalin (NGAL)[J]. J Matern Fetal Neonatal Med, 2010, 23(Suppl 3): 70-72. DOI: 10.3109/14767058.2010.508217.
[2]	KUNZENDORF U, HAASE M, RÖLVER L, et al. Novel aspects of pharmacological therapies for acute renal failure[J]. Drugs, 2010, 70(9): 1099-1114. DOI: 10.2165/11535890-000000000-00000.
[3]	BOLIGNANO D, COPPOLINO G, DONATO V, et al. Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle?[J]. Med Sci Monit, 2010, 16(6): RA131-RA135. http://www.researchgate.net/profile/Giuseppe_Coppolino/publication/44639284_Neutrophil_gelatinase-associated_lipocalin_(NGAL)_a_new_piece_of_the_anemia_puzzle/links/0fcfd509cdf2262bcb000000
[4]	BOLIGNANO D, DONATO V, LACQUANITI A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene[J]. Cancer Lett, 2010, 288(1): 10-16. DOI: 10.1016/j.canlet.2009.05.027.
[5]	CHAKRABORTY S, KAUR S, GUHA S, et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer[J]. Biochim Biophys Acta, 2012, 1826(1): 129-169. DOI: 10.1016/j.bbcan.2012.03.008.
[6]	TRIEBEL S, BLÄSER J, REINKE H, et al. A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase[J]. FEBS Lett, 1992, 314(3): 386-388. DOI: 10.1016/0014-5793(92)81511-j.
[7]	FLOWER DR, NORTH AC, SANSOM CE. The lipocalin protein family: structural and sequence overview[J]. Biochim Biophys Acta, 2000, 1482(1-2): 9-24. DOI: 10.1016/s0167-4838(00)00148-5.
[8]	KJELDSEN L, JOHNSEN AH, SENGELØV H, et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase[J]. J Biol Chem, 1993, 268(14): 10425-10432.
[9]	AXELSSON L, BERGENFELDT M, OHLSSON K. Studies of the release and turnover of a human neutrophil lipocalin[J]. Scand J Clin Lab Invest, 1995, 55(7): 577-588. DOI: 10.3109/00365519509110257.
[10]	KRIZANAC M, MASS SANCHEZ PB, WEISKIRCHEN R, et al. A scoping review on lipocalin-2 and its role in non-alcoholic steatohepatitis and hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(6): 2865. DOI: 10.3390/ijms22062865.
[11]	GOETZ DH, HOLMES MA, BORREGAARD N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition[J]. Mol Cell, 2002, 10(5): 1033-1043. DOI: 10.1016/s1097-2765(02)00708-6.
[12]	KOYNER JL, PARIKH CR. Clinical utility of biomarkers of AKI in cardiac surgery and critical illness[J]. Clin J Am Soc Nephrol, 2013, 8(6): 1034-1042. DOI: 10.2215/CJN.05150512.
[13]	CHIEN MH, YING TH, YANG SF, et al. Lipocalin-2 induces apoptosis in human hepatocellular carcinoma cells through activation of mitochondria pathways[J]. Cell Biochem Biophys, 2012, 64(3): 177-186. DOI: 10.1007/s12013-012-9370-1.
[14]	ASIMAKOPOULOU A, BORKHAM-KAMPHORST E, HENNING M, et al. Lipocalin-2 (LCN2) regulates PLIN5 expression and intracellular lipid droplet formation in the liver[J]. Biochim Biophys Acta, 2014, 1842(10): 1513-1524. DOI: 10.1016/j.bbalip.2014.07.017.
[15]	CHUNG IH, CHEN CY, LIN YH, et al. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer[J]. Oncotarget, 2015, 6(17): 15050-15064. DOI: 10.18632/oncotarget.3670.
[16]	WANG YP, YU GR, LEE MJ, et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway[J]. Hepatology, 2013, 58(4): 1349-1361. DOI: 10.1002/hep.26467.
[17]	XIE Y, LI J, QIN H, et al. Paramylon from Euglena gracilis prevents lipopolysaccharide-induced acute liver injury[J]. Front Immunol, 2022, 12: 797096. DOI: 10.3389/fimmu.2021.797096.
[18]	BORKHAM-KAMPHORST E, DREWS F, WEISKIRCHEN R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation[J]. Liver Int, 2011, 31(5): 656-665. DOI: 10.1111/j.1478-3231.2011.02495.x.
[19]	LABBUS K, HENNING M, BORKHAM-KAMPHORST E, et al. Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions[J]. J Proteomics, 2013, 78: 188-196. DOI: 10.1016/j.jprot.2012.11.021.
[20]	BORKHAM-KAMPHORST E, van de LEUR E, ZIMMERMANN HW, et al. Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis[J]. Biochim Biophys Acta, 2013, 1832(5): 660-673. DOI: 10.1016/j.bbadis.2013.01.014.
[21]	POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
[22]	LAW IK, XU A, LAM KS, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity[J]. Diabetes, 2010, 59(4): 872-882. DOI: 10.2337/db09-1541.
[23]	AUGUET T, TERRA X, QUINTERO Y, et al. Liver lipocalin 2 expression in severely obese women with non alcoholic fatty liver disease[J]. Exp Clin Endocrinol Diabete, 2013, 121(2): 119-124. DOI: 10.1055/s-0032-1331696.
[24]	LU J, LIN L, YE C, et al. Serum NGAL is superior to cystatin C in predicting the prognosis of acute-on-chronic liver failure[J]. Ann Hepatol, 2019, 18(1): 155-164. DOI: 10.5604/01.3001.0012.7907.
[25]	MILNER KL, van der POORTEN D, XU A, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease[J]. Hepatology, 2009, 49(6): 1926-1934. DOI: 10.1002/hep.22896.
[26]	XU Y, ZHU Y, JADHAV K, et al. Lipocalin-2 protects against diet-induced nonalcoholic fatty liver disease by targeting hepatocytes[J]. Hepatol Commun, 2019, 3(6): 763-775. DOI: 10.1002/hep4.1341.
[27]	SEMBA T, NISHIMURA M, NISHIMURA S, et al. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis[J]. BMC Gastroenterol, 2013, 13: 120. DOI: 10.1186/1471-230X-13-120.
[28]	ASIMAKOPOULOU A, BORKHAM-KAMPHORST E, TACKE F, et al. Lipocalin-2 (NGAL/LCN2), a "help-me" signal in organ inflammation[J]. Hepatology, 2016, 63(2): 669-671. DOI: 10.1002/hep.27930.
[29]	YE D, YANG K, ZANG S, et al. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2[J]. J Hepatol, 2016, 65(5): 988-997. DOI: 10.1016/j.jhep.2016.05.041.
[30]	KIM HG, HUANG M, XIN Y, et al. The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice[J]. J Hepatol, 2019, 71(5): 960-969. DOI: 10.1016/j.jhep.2019.06.019.
[31]	WIESER V, TYMOSZUK P, ADOLPH TE, et al. Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease[J]. J Hepatol, 2016, 64(4): 872-880. DOI: 10.1016/j.jhep.2015.11.037.
[32]	ZHANG Y, LONG X, RUAN X, et al. SIRT2-mediated deacetylation and deubiquitination of C/EBPβ prevents ethanol-induced liver injury[J]. Cell Discov, 2021, 7(1): 93. DOI: 10.1038/s41421-021-00326-6.
[33]	BATALLER R, BRENNER DA. Liver fibrosis[J]. J Clin Invest, 2005, 115(2): 209-218. DOI: 10.1172/JCI24282.
[34]	ARIZA X, GRAUPERA I, COLL M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis[J]. J Hepatol, 2016, 65(1): 57-65. DOI: 10.1016/j.jhep.2016.03.002.
[35]	KIM JW, LEE SH, JEONG SH, et al. Increased urinary lipocalin-2 reflects matrix metalloproteinase-9 activity in chronic hepatitis C with hepatic fibrosis[J]. Tohoku J Exp Med, 2010, 222(4): 319-327. DOI: 10.1620/tjem.222.319.
[36]	CHEN J, ARGEMI J, ODENA G, et al. Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension[J]. Sci Rep, 2020, 10(1): 15558. DOI: 10.1038/s41598-020-72172-7.
[37]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[38]	CANDIDO S, MAESTRO R, POLESEL J, et al. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer[J]. Oncotarget, 2014, 5(6): 1576-1594. DOI: 10.18632/oncotarget.1738.
[39]	BARSOUM I, ELGOHARY MN, BASSIONY MAA. Lipocalin-2: A novel diagnostic marker for hepatocellular carcinoma[J]. Cancer Biomark, 2020, 28(4): 523-528. DOI: 10.3233/CBM-190084.
[40]	ABDELSAMEEA E, NADA A, OMAR N, et al. Urine neutrophil gelatinase-associated lipocalin a possible diagnostic marker for egyptian hepatocellular carcinoma patients[J]. Asian Pac J Cancer Prev, 2020, 21(8): 2259-2264. DOI: 10.31557/APJCP.2020.21.8.2259.
[41]	ZHANG Y, FAN Y, MEI Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification[J]. Cancer Epidemiol, 2012, 36(5): e294-e299. DOI: 10.1016/j.canep.2012.05.012.
[42]	DERTLI R, BIYIK M, YOLACAN R, et al. May neutrophil gelatinase-associated lipocalin (NGAL) level predict mortality in patients with hepatocellular carcinoma (HCC)?[J]. J Gastrointest Cancer, 2020, 51(3): 932-938. DOI: 10.1007/s12029-019-00323-9.
[43]	YAO F, DENG Y, ZHAO Y, et al. A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis[J]. Nat Commun, 2021, 12(1): 7333. DOI: 10.1038/s41467-021-27452-9.
[44]	LEE EK, KIM HJ, LEE KJ, et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling[J]. Int J Oncol, 2011, 38(2): 325-333. DOI: 10.3892/ijo.2010.854.